Literature DB >> 19301941

Pharmacokinetic interaction of ciprofloxacin with diclofenac: a single-dose, two-period crossover study in healthy adult volunteers.

Zafar Iqbal1, Abbas Khan, Attiqa Naz, Jamshaid A Khan, Ghulam S Khan.   

Abstract

BACKGROUND AND
OBJECTIVE: Ciprofloxacin is a broad-spectrum, synthetic antibacterial used for the treatment of various bacterial infections. In multidrug therapy, ciprofloxacin is commonly prescribed with analgesics for the management of infection, pain and inflammation. The objective of this study was to evaluate the pharmacokinetic properties of ciprofloxacin tablets with concurrent administration of diclofenac tablets in healthy adult human volunteers. METHODS AND
DESIGN: The disposition pharmacokinetics of a single oral dose of ciprofloxacin 500 mg alone and with co-administration of a diclofenac 50 mg tablet in 12 healthy male volunteers was investigated using a two-period, crossover design. The blood samples were collected at 0 (predose), 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16 and 24 hours after administration of the drugs and the concentration of ciprofloxacin in serum was determined using reversed phase high-performance liquid chromatography. The pharmacokinetic parameters were calculated using a noncompartmental model and a two-compartment model.
RESULTS: The maximum plasma concentration (C(max)) of ciprofloxacin increased from 2.48 +/- 0.33 microg/mL when administered alone to 3.91 +/- 0.8 microg/mL with co-administration of diclofenac. Time to reach C(max) (t(max)) with ciprofloxacin reduced from 2.02 +/- 0.3 hours when administered alone to 1.49 +/- 0.2 h with co-administration of diclofenac. Significant increases in ciprofloxacin area under the serum concentration-time curve (AUC) and elimination half-life, together with a significant decrease in total body clearance of ciprofloxacin, were observed with concurrent administration of diclofenac.
CONCLUSION: Oral co-administration of ciprofloxacin tablets with diclofenac tablets increased ciprofloxacin AUC and C(max), and reduced ciprofloxacin t(max) and total body clearance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19301941     DOI: 10.2165/00044011-200929040-00006

Source DB:  PubMed          Journal:  Clin Drug Investig        ISSN: 1173-2563            Impact factor:   2.859


  20 in total

1.  Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension.

Authors:  A Shah; M C Liu; D Vaughan; A H Heller
Journal:  J Antimicrob Chemother       Date:  1999-03       Impact factor: 5.790

2.  Pharmacokinetic interaction of tetracycline with non-steroidal anti-inflammatory drugs via organic anion transporters in rats.

Authors:  Yo-Han Oh; Hyo-Kyung Han
Journal:  Pharmacol Res       Date:  2005-10-10       Impact factor: 7.658

3.  Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.

Authors:  C Seral; M Barcia-Macay; M P Mingeot-Leclercq; P M Tulkens; F Van Bambeke
Journal:  J Antimicrob Chemother       Date:  2005-02-24       Impact factor: 5.790

4.  A multiple-dose pharmacokinetic interaction study between didanosine (Videx) and ciprofloxacin (Cipro) in male subjects seropositive for HIV but asymptomatic.

Authors:  C A Knupp; R H Barbhaiya
Journal:  Biopharm Drug Dispos       Date:  1997-01       Impact factor: 1.627

5.  Pharmacokinetics of ciprofloxacin in impaired liver function.

Authors:  S Esposito; M Miniero; D Barba; E Sagnelli
Journal:  Int J Clin Pharmacol Res       Date:  1989

6.  Organic anion transporter 3 (oat3/slc22a8) interacts with carboxyfluoroquinolones, and deletion increases systemic exposure to ciprofloxacin.

Authors:  Adam L Vanwert; Chutima Srimaroeng; Douglas H Sweet
Journal:  Mol Pharmacol       Date:  2008-04-01       Impact factor: 4.436

Review 7.  Fluoroquinolones: structure and target sites.

Authors:  P G Higgins; A C Fluit; F J Schmitz
Journal:  Curr Drug Targets       Date:  2003-02       Impact factor: 3.465

8.  Absorption of ciprofloxacin in febrile and afebrile patients.

Authors:  K B Patel; P P Belliveau; C H Nightingale; D P Nicolau; R Quintiliani
Journal:  Int J Antimicrob Agents       Date:  1995-12       Impact factor: 5.283

9.  Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.

Authors:  U Jaehde; F Sörgel; A Reiter; G Sigl; K G Naber; W Schunack
Journal:  Clin Pharmacol Ther       Date:  1995-11       Impact factor: 6.875

Review 10.  Absorption interactions with fluoroquinolones. 1995 update.

Authors:  B M Lomaestro; G R Bailie
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

View more
  4 in total

Review 1.  [Polypharmacy and pain treatment].

Authors:  Markus Gosch; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Bernhard Iglseder; Monika Lechleitner; Ronald Otto; Regina E Roller; Ulrike Sommeregger
Journal:  Wien Med Wochenschr       Date:  2010-06

2.  [Analgesics in geriatric patients. Adverse side effects and interactions].

Authors:  Markus Gosch
Journal:  Z Gerontol Geriatr       Date:  2015-07       Impact factor: 1.281

3.  Pain management for dentists: the role of ibuprofen.

Authors:  Alessandro Pozzi; Luca Gallelli
Journal:  Ann Stomatol (Roma)       Date:  2012-04-15

4.  Pharmacokinetic interaction between zolpidem and ciprofloxacin in healthy volunteers.

Authors:  Laurian Vlase; Adina Popa; Maria Neag; Dana Muntean; Sorin E Leucuţa
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2010-10-05       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.